COMMUNIQUÉS West-GlobeNewswire

-
Synfini Inc. and O2nix Bio Announce Strategic Collaboration to Develop Novel Cancer Therapeutics Targeting FTSJ1
18/06/2025 -
INVO Fertility Expands Telehealth Capabilities at Its Wisconsin Fertility Institute
18/06/2025 -
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
18/06/2025 -
Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board
18/06/2025 -
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
18/06/2025 -
Sienna Senior Living Completes Second Acquisition in Ottawa in 2025
18/06/2025 -
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
18/06/2025 -
Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion
18/06/2025 -
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
18/06/2025 -
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
18/06/2025 -
R1 Appoints Dave Wojczynski as President to Lead Physician Revenue Cycle Management Business
18/06/2025 -
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
18/06/2025 -
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
18/06/2025 -
Route 92 Medical Appoints Medtech Industry Veterans Mitch Hill and Lucas Buchanan to its Board of Directors
18/06/2025 -
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
18/06/2025 -
Cannara Reduces Cost of Debt with Lower Interest Rate and Partial Debenture Repayment; Wins 2025 Brand of the Year
18/06/2025 -
Cannara réduit le coût de sa dette en abaissant son taux d’intérêt et en remboursant partiellement sa débenture convertible ; remporte le prix de la marque de l’année 2025
18/06/2025 -
Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue Streams
18/06/2025 -
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
18/06/2025
Pages